Advent Life Sciences leads series-A for CN Creative

The new capital from the all-equity round will be used to finalise the company's latest product Nicadex.

Company
CN Creative is based in the Bioscience Incubator at Manchester University. The company develops products and services focused on smoking cessation. Its product portfolio includes QuitDirect, an NHS-accredited service supplier; Intellicig, an electronic cigarette; and NRT Direct, a high purity nicotine preparation. Its products are sold in 26 countries. Currently, Nicadex, an electronic inhaler, is being tested in clinical trials.

The company was founded in 2008 and has 40 staff. CN Creative expects to generate £2.6m in turnover in 2012.

People
Dale Pfost, general partner at Advent Life Sciences, has been named chairman of CN Creative. Kaasim Mahmood, partner at Advent Life Sciences, will join the board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• UK / Ireland
• Expansion